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Background: In recent years, studies have sought to understand the mechanisms involved in the alteration of
autophagic flux in Alzheimer's disease (AD). Alongside the recent description of the impairment of lysosomal
acidification, we wanted to study the relationships between inflammation and autophagy, two physiological
components deregulated in AD. Therefore, a longitudinal study was performed in APPswePS1dE9 transgenic mice
at three, six and twelve months of age.
Methods: Autophagic markers (Beclin-1, p62 and LC3) and the activation of mammalian Target of Rapamycin
(mTOR) signaling pathway were quantified by western blot. Cytokine levels (IL-1β, TNF-α and IL-6) were measured
by ELISA. Transmission electron microscopy was performed to detect autophagic vacuoles. Mann-Whitney tests
were used to compare wild-type (WT) versus APPswePS1dE9 mice. Longitudinal changes in parameters were
analyzed with a Kruskal-Wallis test followed by a post-hoc Dunn’s test. Correlation between two parameters was
assessed using a Spearman test.
Results: Compared to 12-month old WT mice, 12-month old APPswePS1dE9 mice had higher levels of IL-1β and
TNF-α, a greater inhibition of the mTOR signaling pathway and lower levels of Beclin-1 expression both in cortex
and hippocampus. Regarding the relationship of the various parameters in 12-month old APPswePS1dE9 mice,
Beclin-1 rates were positively correlated with IL-1β and TNF-α levels. And, on the contrary, TNF-α levels were inversely
correlated with the levels of mTOR activation. Altogether, these results suggest that inflammation could induce
autophagy in APPswePS1dE9 mice. However, these transgenic mice displayed a large accumulation of autophagic
vesicles within dystrophic neurons in cortex and hippocampus, indicating a terminal failure in the autophagic
process.
Conclusions: This first demonstration of relationships between inflammation and autophagy in in vivo models of
AD should be taken into account in new therapeutic strategies to prevent inflammation and/or stimulate
autophagy in advanced neurodegenerative process such as AD.
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Alzheimer's disease (AD) is a progressive dementia with
atrophy, senile plaques of fibrillogenic beta-amyloid (Aβ)
and intraneuronal neurofibrillary tangles with hyperpho-
sphorylated tau. In 1988, it was discovered that microglia
around Aβ deposits expressed major histocompatibility
complex type II, a marker for activated immune cells
[1-4]. However, the notion that the CNS is an immuno-
logically privileged organ is questioned and microglia
are generally recognized as the brain’s resident players
in innate immune/inflammatory responses in AD. Like
microglia, reactive astrocytes encircle Aβ deposits in a
manner reminiscent of glial scarring [5-7]. In addition,
many molecular mediators are involved in the inflamma-
tory response in AD, including complement factors, cyto-
kines, chemokines, pattern recognition receptors, scavenger
receptors, cyclooxygenases and reactive oxygen species
[8-11]. Several data from literature are in favor of a dele-
terious role of inflammation, in particular the activation of
the inflammasome [10,12-15], but more research is
needed to better understand its role according to the stage
of the disease and the many failures of anti-inflammatory
therapies in patients with AD.
It is known that peripheral inflammation plays a role
in cell proteolysis; in particular, molecular relationships
were identified with macroautophagy (called autophagy)
which degrades long-lived proteins and organelles [16-21].
Autophagy has an anti-inflammatory function as dem-
onstrated in a mouse model of Crohn’s disease [22] and
many studies have shown that autophagy targets ubiquiti-
nated aggregated inflammasome components for destruc-
tion [23-26]. Autophagy may have a protective role against
the development of a number of neurodegenerative
diseases [27,28]. Autophagy deregulation was initially
linked to AD when electron microscopy studies revealed
the accumulation of autophagic vacuoles in the brains of
AD patients [29,30]. Compelling evidence indicates that
Aβ is generated in autophagic vacuoles during autophagy,
suggesting that autophagy may exacerbate AD pathogen-
esis by increasing Aβ levels [31-33]. Furthermore, clear-
ance of autophagic vacuoles is impaired in AD brains [34]
and one probable contributor to autophagy deficiency in
AD appears to be Beclin-1, whose expression is strongly
reduced in the brains of AD patients to levels that would
be predicted to impair autophagosome synthesis [35,36].
The relationships between autophagy and inflammation in
AD have not yet been explored in vivo. This present study
aims to track key inflammatory cytokine actors (IL-1β,
TNF-α and IL-6) and autophagy markers (Beclin-1, p62
and microtubule-associated protein 1/light chain 3 (LC3))
in APPswePS1dE9 transgenic mice. These mice are used
extensively in research and have a significant inflamma-
tory response at 12 months. However, their autophagic
status has never been followed over time.Materials and methods
Chemical products
Sodium fluoride (NaF), phenylmethylsulfonyl fluoride
(PMSF), protease and phosphatase inhibitor cocktails,
dithiothreitol (DTT), paraformaldehyde (PFA) and all
reagent-grade chemicals for buffers were purchased from
Sigma (St Quentin Fallavier, France); sodium pentobarbital
from CEVA, Animal Health (Libourne, France); NuPAGE®
LDS 4X Sample Buffer, NuPAGE® Sample Reducing Agent
(10X), Novex® 4 to 20% Tris-Glycine Mini gels, NuPAGE®
3 to 8% Tris-Acetate gels, Novex® Tris-Glycine SDS
Running Buffer and NuPAGE® Tris-Acetate SDS Running
Buffer, NuPAGE® Antioxidant, Seeblue® Plus2 pre-stained
standard, iBlot® Gel Transfer Device (EU), Quant-it® protein
assay from Gibco-Invitrogen (Fisher Bioblock Scientific
distributor, Illkirch, France); 4X Laemmli Sample Buffer,
4 to 15% mini-PROTEAN® TGX™ gels, Tris-Glycine
Running Buffer and Trans-Blot® Turbo™ Transfer System
from Bio-Rad (Marnes-la-Coquette, France).
For western blot, primary antibodies and secondary
anti-rabbit IgG antibody conjugated with horseradish
peroxidase (HRP) were purchased from Cell Signalling
(Ozyme, Saint-Quentin-en-Yvelines, France) except seques-
tosome 1 (p62/SQMT1) from MBL (CliniSciences distribu-
tor, Nanterre, France), anti-β tubulin from Sigma (St
Quentin Fallavier, France), HRP-conjugated anti-mouse
IgG from Amersham Biosciences (Orsay, France), IgG-
and protease-free BSA from Jackson ImmunoResearch
Europe Ltd (Interchim distributor, Montluçon, France).
Molecular biology reagents were obtained from Promega
(Charbonnières, France).
Animals
Male hemizygote B6C3-Tg (APPswe, PS1dE9)85Dbo
(stock #004462) and female wild-type (WT) mice (B6C3F1,
stock #10010) were obtained from Jackson Laboratories
(Bar Harbor, ME USA) and bred to create colonies of
APPswePS1dE9 and WT mice. As described in the web-
site of Jackson Laboratories, two expression plasmids
(Mo/HuAPP695swe and PS1-dE9) were designed to each
be controlled by independent mouse prion protein (PrP)
promoter elements, directing transgene expression pre-
dominantly to central nervous system (CNS) neurons. The
Mo/HuAPP695swe transgene expresses a ‘humanized’
mouse amyloid beta (A4) precursor protein gene modi-
fied at three amino acids to reflect the human residues
and further modified to contain the K595N/M596L
mutations linked to familial Alzheimer’s disease (FAD).
The PS1dE9 transgene expresses a mutant human prese-
nilin 1 carrying the exon-9-deleted variant (PSEN1dE9)
associated with FAD. Occasional deposits can be found in
mice as young as six months of age and plaques are abun-
dant in hippocampus and cortex by nine months of age.
Furthermore, in this APPswePS1dE9 mouse model of AD,
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develop at early stage of the life and progressively increase
with age [36,37].
Mice derived from crosses of 12 breeders. At weaning,
all mice were tattooed (ISO Tiny chip, Biolog-id, Bernay,
France), genotyped by PCR analysis of tail biopsies ac-
cording to the manufacturer’s recommended protocol
(KAPA Mouse Genotyping HotStart Kit, CliniSciences,
Nanterre, France).
The use of animals for this study was approved by the
Ethical and Animal Care Committee at ‘La direction
départementale de la protection de la population (DDPP)’
(registration number: 06.12). An agreement was obtained
from The High Council of Biotechnology for transgenic
animals in 2010 (5418 number agreement). All animal
care and experimental procedures conformed with the
French Décret number 2013-118, 1 February 2013 NOR:
AGRG1231951D in accordance to European Community
guidelines (directive 2010/63/UE for the Care and Use of
Laboratory Animals). All efforts were made to minimize
animal suffering as well as the number of animals used.
The animals were housed in a conventional state under
adequate temperature (23 ± 3°C) and relative humidity
(55 ± 5%) control with a 12/12 hour reversed light/dark
cycle, and provided with food and water ad libitum.
Brain tissue preparation for biochemical analysis
At 3, 6 and 12 months of age, mice were transcardially
perfused with PBS (154 mM NaCl, 1.54 mM KH2PO4,
2.7 mM Na2HPO4.7H2O, pH 7.2) after deep anesthesia
with pentobarbital (80 mg/kg, intraperitoneally (ip)). Brains
were rapidly removed and dissected on ice. Cortex and
hippocampus were homogenized using 10 up-and-down
strokes of a prechilled Teflon-glass homogenizer in 20
volumes of lysis buffer (25 mM Tris-HCl, 150 mM NaCl,
1 mM EDTA, pH 7.4) and supplemented with 50 mM
NaF, 1 mM PMSF, protease and phosphatase inhibitor
cocktails (50 μL/g of tissue and 10 μL/mL of lysis buffer,
respectively). Lysates were sonicated and centrifuged at
15,000 g for 15 minutes at 4°C. The resulting supernatants
were collected for Quant-it® protein assay according to the
manufacturer’s protocol. Samples were stored at −20°C
until ELISA and immunoblotting described below. For
q-PCR, a piece (10 mg of tissue) of cortex and hippo-
campus was immediately homogenized in RNA lysis
buffer available in the kit from Promega by using sterile
25-gauge needle and syringe. These samples were stored
at −80°C until RNA extraction.
TaqMan real-time PCR
Total RNA was isolated from cortex and hippocampus
by using SV Total RNA Isolation System according to
the manufacturer’s instructions (Promega, Charbonnieres,
France). Concentration of total RNA was measured byusing a nanodrop (Nanodrop 2000 spectrophotometer,
ThermoScientific (Villebon sur Yvette, France). Total
RNA isolate (500 ng) was converted into first strand
cDNA using ImProm-II™ Reverse Transcription System
(Promega, Charbonnieres, France) .
The TaqMan probes and primers were designed accord-
ing to the sequence of murine p62, LC3, Beclin-1 and S6
ribosomal protein genes using the Primer Express soft-
ware version 2.0 (ABI Applied Biosystems, Foster City,
CA, USA). Primers p62-F (5′-CTGCACAGGGAACACA
GCAA-3′) and p62-R (5′ GCCAGCGGCTATGAGAGA
AG-3′), LC3-F (5′-TCGCCGACCGCTGTAAG-3′) and
LC3-R (5′-CTCGATGATCACCGGGATCT-3′), Beclin-F
(5′-CTGCACAGGGAACACAGCAA-3′) and Beclin-R
(5′-GCCAGCGGCTATGAGAGAAG-3′) and S6-F (5′-A
AGTCGGGCCTCTTTTTCGT-3′) and S6-R (5′ GGGAA
GGAGATGTTCAGCTTCA-3′) were designed to yield
respectively a 79 bp, 71 bp, 146 bp and 73 bp fragments
of the p62, LC3, Beclin-1 and S6 ribosomal protein
genes. The TaqMan probes p62-P (5′-TCCCAACCC
CTTTGGCCACCTCT-3′), LC3-P (5′-TCCGCGACC
AGCACCCCAG-3′), Beclin-P (5′- CCTTCCACATC
TGGCACAGCGGA-3′); S6-P (5′-CCTCCCAGGCGC
TCGGCTG-3′); contained 6-carboxy-fluorescein (FAM)
reporter dye at the 5′ end and 6-carboxytetramethylrho-
damine (TAMRA) fluorescent quencher at the 3′ end.
Primers and probes were commercially synthesized by
Eurogentec (Angers, France). TaqMan real-time PCR
was performed in an ABI 7500 real-time PCR system
(Applied Biosystems, Foster City, CA, USA). Amplifica-
tion reaction contained 2X TaqMan Universal Master Mix
(Applied, Villebon-sur-Yvette, France), 900 nM of each
primer (p62-F and p62-R or LC3-F and LC3-R or Beclin-
1-F and Beclin-R), 900 nM of probe and cDNA template
and nuclease-free water to a final volume of 13 μL. The
thermal profile consisted of 50°C for 2 minutes, followed by
95°C for 10 minutes and 40 cycles of 95°C for 15 seconds
and 59°C for 1 minute. Fluorescence was measured once
per cycle at the end of the 59°C segment.
The standard curve was generated using 10-fold serial
dilutions with ddH2O from 10
−1 to 10−6 cDNA synthesized
from RNA of lipopolysaccharide (LPS)-treated mouse
spleen (positive control). The PCR conditions for this
standard curve were adopted to perform the further re-
actions to estimate transcriptional expression of p62,
LC3 and Beclin-1 by TaqMan real-time PCR assay. For
each gene and structure, results were normalized rela-
tively to mean of WT mice.
ELISA
Commercially available ELISA kits were used for asses-
sing IL-1β (sensitivity: 16 pg/mL) TNF-α (sensitivity:
4 pg/mL) and IL-6 (sensitivity: 2 pg/mL) according to
the manufacturers' instructions (BioLegend, Ozyme,
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lysis was between 31.3 to 2,000 pg/mL for IL-1β and
7.8 to 500 pg/mL for TNF-α and IL-6. Homogenates
from brain tissue (50 mg of tissue/mL) were added in
each well of pre-coated plates and all steps were performed
at room temperature (RT). The enzymatic reaction was
stopped after 15 minutes incubation with tetramethyl-
benzidine (TMB) substrate by adding 2 N H2SO4 and
the optical density (OD) was read at 450 nm within
30 minutes, using the Multiskan® spectrum spectropho-
tometer (ThermoScientific, Villebon sur Yvette, France).
The cytokine levels were then calculated by plotting the
OD of each sample against the standard curve. The
intra- and inter-assay reproducibility was > 90%. OD
values obtained for duplicates that differed from the
mean by greater than 10% were not considered for fur-
ther analysis. For convenience, all results are expressed
in pg/mg protein.
Immunoblottings
Samples (40 μg proteins) were prepared for electrophor-
esis by adding NuPAGE® 4X LDS Sample Buffer and
NuPAGE® Sample Reducing Agent (10X). Samples were
then heated up 100°C for 5 minutes, loaded into Novex®
4 to 20% Tris-Glycine mini Gels, run at 150 V for 60 mi-
nutes in Novex® Tris-Glycine SDS Running Buffer and
in NuPAGE® 3 to 8% Tris-Acetate Gels, run at 125 V for
120 minutes in NuPAGE® Tris-Acetate SDS Running
Buffer containing NuPAGE antioxidant. Gels were trans-
ferred to nitrocellulose membranes using the iBlot® Dry
blotting system set to program 20 V for 7 minutes. For LC3
analysis, we used Trans-Blot® Turbo™ Transfer System
(25 V, 3 minutes for 0.2 μm nitrocellulose MISI format)
after protein gel electrophoresis of samples prepared in
4X Laemmli Sample Buffer and loaded into 4 to 15%
mini-PROTEAN® TGX™ gels with Tris-Glycine SDS
Running Buffer.
Membranes were washed for 10 minutes in Tris-buffered
saline/Tween (TBST: 20 mM Tris-HCl, 150 mM NaCl,
pH 7.5, 0.05% Tween 20) and not specific antigenic sites
were blocked for 2 hours in TBST containing 5% BSA.
Blots were incubated with primary antibody in blocking
buffer overnight at 4°C. Antibodies used were rabbit
anti-PS2448-mTOR, anti-total mTOR, anti-PT389-p70S6K,
anti-total p70S6K, anti-Beclin-1, anti-p62, anti-LC3, all
at 1:500 dilution factor. Membranes were washed twice
with TBST and then incubated with the HRP-conjugated
secondary antibody anti-rabbit IgG (1:1,000), during 1 hour
at RT. Membranes were washed again and exposed to
the chemiluminescence Luminata Forte Western HRP
Substrate (Millipore, Saint-Quentin-en-Yvelines, France)
followed by signal capture with the Gbox system (GeneS-
nap software, Syngene, Ozyme distributor, Saint-Quentin-
en-Yvelines, France). After 2 washes in TBST, membraneswere probed with mouse antibody against β-tubulin
(1:10,000) overnight at 4°C. They were then washed
with TBST, incubated with HRP-conjugated secondary
antibody anti-mouse (1:1,000) for 1 hour, exposed to the
chemiluminescence Luminata classico substrate (Millipore,
Saint-Quentin-en-Yvelines, France) and signals were
captured. Automatic image analysis software is supplied
with Gene Tools (Syngene, Ozyme distributor, Saint-
Quentin-en-Yvelines, France). Protein/β-tubulin ratios
were calculated and shown in the corresponding figures.
Phospho-protein/total protein ratios were calculated to
evaluate rates of protein activation.
Transmission electron microscopy (TEM)
For brain TEM, four mice were transcardially perfused
with PBS followed by 4% PFA perfusion after deep
anesthesia with pentobarbital (80 mg/kg, ip). Brains were
rapidly removed on ice and thin sagittal sections were
isolated and fixed with 3% glutaraldehyde in PBS (0.1 M;
pH = 7.4) for 2 hours at 4°C. Samples (2 mm3 of tissue
in cortex and hippocampus) were then washed three
times (3 × 10 minutes) in PBS before being post-fixed in
1% osmium tetroxide in PBS for 1 hour at 4°C, processed
through a graded acetone series, embedded in Araldite
(Fluka, Buchs, Switzerland) and polymerized overnight at
60°C. Thin sections (60 nm) were cut with a diamond
knife on Reichert Ultracut (Leica, Nanterre, France) S,
recovered on Cu grids and contrasted with uranyl acet-
ate (4%) and lead citrate and were observed under a
JEOL 1010 transmission electron microscope (Jeol Ltd,
Tokyo, Japan).
Statistical analysis
For biochemical analysis, results are expressed as means ±
SEM. To compare quantitative variables between WT mice
and APPswePS1dE9 mice, Mann-Whitney tests were used.
Comparisons between the three classes of age in both
groups of mice were performed using a Kruskal-Wallis test
followed by a post-hoc Dunn’s test. Correlations between
two quantitative parameters in APPswePS1dE9 mice were
estimated by Spearman tests (GraphPad Instat, GraphPad
Software, San Diego, CA, USA). The level of significance
was P < 0.05.
Results
Longitudinal monitoring of cytokines in the brain of
APPswePS1dE9 mice
IL-1β levels in APPswePS1dE9 mice were significantly
higher in cortex (3.1-fold) and hippocampus (4.5-fold) than
those of WT mice only at 12 months of age. Furthermore,
12-month old APPswePS1dE9 mice produced more IL-1β
than 3-month old APPswePS1dE9 mice (6.8-fold in cortex,
6-fold in hippocampus) and 6-month old APPswePS1dE9
mice (3.25-fold in cortex and 3.9-fold in hippocampus),
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old APPswePS1dE9 mice than in respective WT mice
(2.3-fold) in hippocampus only (Figure 1B and D). For
IL-6 levels, no difference between the two groups of
mice at 12 months of age was observed in both brain
areas (cortex: 2.13 ± 0.33 and 2.94 ± 0.59 pg/mg protein
for APPswePS1dE9 and WT mice, respectively; hippo-
campus: 3.30 ± 0.37 and 2.82 ± 0.49 pg/mg protein for
APPswePS1dE9 and WT mice, respectively).
Changes in activation of the mTOR signaling pathway
mTOR activation leads to phosphorylation of various
substrates, in particular p70S6K at T389, a ribosomal S6
kinase involved in ribogenesis [38,39]. Furthermore, it is
also well known that autophagy is inhibited by the acti-
vation of the mTOR signaling [40].
In APPswePS1dE9 mice, the activation of mTOR and
p70S6K decreased with age (Figure 2). Indeed, significant
decreases were observed in 12-month old APPswePS1dE9
mice compared to WT mice (56% and 63.7% in cortex,
41.6% and 53.2% in hippocampus for mTOR and p70S6K,Figure 1 Longitudinal monitoring of cytokines in the brain of APPswe
cortex (A and B) and hippocampus (C and D) of APPswePS1dE9 (APP) and
levels were expressed in pg/mg protein. Results are mean ± SEM of 12 mic
by a Mann-Whitney test: **P < 0.01, ***P < 0.001; comparison of the 3 classes
(Dunn’s multiple comparison test in APP mice): #P < 0.05 for 6-month old v
12-month old APP mice.respectively). Furthermore, the activation of mTOR and
p70S6K in twelve-month old APPswePS1dE9 mice was
significantly different compared to transgenic mice at
three and six months of age (Figure 2). Interestingly, the
mTOR signaling pathway impairment was observed from
6-month old APPswePS1dE9 mice in hippocampus
(decrease in 58.8% and 36% for mTOR and p70S6K
compared to WT mice, respectively) and mTOR activa-
tion in 12-month old APPswePS1dE9 mice was signifi-
cantly different compared to 3-month old APPswePS1dE9
mice (Figure 2C and D).
Longitudinal monitoring of autophagy markers in the
brain of APPswePS1dE9 mice
To explore autophagy in both groups of mice, immu-
noblottings of Beclin-1, p62, LC3-I and LC3-II were
performed. The levels of expression of Beclin-1, which is a
key component in the initiation of autophagosome forma-
tion [41], decreased in 12-month old APPswePS1dE9 mice
(57% and 36.8% in cortex and hippocampus compared to
12-month old WT mice, respectively). Regarding autophagyPS1dE9 mice. IL1-β and TNF-α levels were measured by ELISA in
wild-type mice (WT) at three, six and twelve months of age. Cytokine
e in each group. Comparison between APP and WT mice at each age
of age (Kruskall-Wallis test) followed by two-by-two comparisons
ersus 12-month old APP mice, ###P < 0.001 for 3-month old versus
Figure 2 Changes in activation of the mammalian Target of Rapamycin (mTOR) signaling pathway. Representative immunoblots of
PS2448-mTOR (289 kDa), total mTOR (289 kDa), PT389-p70S6K (70 kDa), total p70S6K (70 kDa) in cortex (A and B) and hippocampus (C and D) of
wild-type (WT) mice and APPswePS1dE9 (APP) at 3, 6 and 12 months of age. Semi-quantitative analysis of immunoblot was performed using
Gene Tools software (Syngene, Ozyme, Saint-Quentin-en-Yvelines, France). The immunoreactivity of protein was normalized to β-tubulin
(55 kDa) immunoreactivity. The results are expressed as arbitrary units (% of WT). Results are mean ± SEM of 12 mice. Comparison between APP
and WT mice at each age by a Mann-Whitney test: **P < 0.01, ***P < 0.001; comparison of the 3 classes of age (Kruskall-Wallis test) followed by
two-by-two comparisons (Dunn’s multiple comparison test in APP mice): $$P < 0.01 for 3-month old versus 6-month old APP mice, #P < 0.05,
##P < 0.01 for 6-month old versus 12-month old APP mice.
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Beclin-1 expression in twelve-month old APPswePS1dE9
mice were also significantly lower than those of six-month
old APPswePS1dE9 mice in hippocampus and three-month
old APPswePS1dE9 mice in both brain areas (Figure 3A
and C).p62 is an autophagic receptor which recognizes ubiqui-
tinylated proteins and interacts with LC3-II at the forming
autophagosome [42]. LC3 is present in free cytoplasmic
form as LC3-I which, when is associated to phosphati-
dylethanolamine (through an ubiquitin-like conjugation
reaction) of the membrane of autophagosome, produces
Figure 3 Longitudinal monitoring of Beclin-1 and p62 in the brain of APPswePS1dE9 mice. Representative immunoblots of Beclin-1 (60 kDa)
and p62 (62 kDa) in cortex (A and B, respectively) and hippocampus (C and D, respectively) of wild-type (WT) and APPswePS1dE9 (APP) mice at 3, 6
and 12 months of age. Semi-quantitative analysis of immunoblot was performed using Gene Tools software (Syngene, Ozyme, Saint-Quentin-en-
Yvelines, France). The immunoreactivity of protein was normalized to β-tubulin (55 kDa) immunoreactivity. The results are expressed as arbitrary units
(% of WT). Results are mean ± SEM of 12 mice. Comparison between APP and WT mice at each age by a Mann-Whitney test: ***P < 0.001; Comparison
of the three classes of age (Kruskall-Wallis test) followed by two-by-two comparisons (Dunn’s multiple comparison test in APP mice): #P < 0.05,
##P < 0.01 compared to 12-month old APPswePS1dE9.
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[42]. Results showed that the p62 expression decreased
in cortex of APPswePS1dE9 mice at 12 months of age (30%
compared to WT mice) and was significantly different
compared to 3-month old APPswePS1dE9 mice (Figure 3B
and D). Contrary to Beclin-1 and p62, no change was
observed in expressions of LC3-I and LC3-II (Figure 4).
As protein changes of autophagy were observed only at
12 months of age, a transcriptional analysis was performed
to complete this monitoring and data showed no significantdifference for all markers between APPswePS1dE9 and
WTat 12 months of age (Table 1).
In addition, TEM revealed the presence of dystrophic
neurites with a large accumulation of autophagic vesicles
(AVs) with a dense compacted amorphous or multila-
mellar content both in cortex and hippocampus in
APPswePS1dE9 mice at 12 months of age (Figure 5). No
AVs and no dystrophic neurites were depicted at three
and six months of age in these transgenic mice (data not
shown).
Figure 4 Longitudinal monitoring of LC3 in the brain of APPswePS1dE9 mice. Representative immunoblots of LC3-I (18 kDa), LC3-II (16 kDa)
in cortex (A and B, respectively) and hippocampus (C and D, respectively) of wild-type (WT) and APPswePS1dE9 (APP) mice at 3, 6 and 12 months
of age. Semi-quantitative analysis of immunoblot was performed using Gene Tools software (Syngene, Ozyme, Saint-Quentin-en-Yvelines, France).
The immunoreactivity of protein was normalized to β-tubulin (55 kDa) immunoreactivity. The results are expressed as arbitrary units (% of WT).
Results are mean ± SEM for 12 mice.
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and hippocampus of APPswePS1dE9 mice
In the 12-month old APPswePS1dE9 mouse group, in-
flammation and autophagy were significantly correlated.
Indeed, Beclin-1 and IL-1β levels in cortex and in hippo-
campus were positively correlated (Figure 6). In addition,Table 1 Monitoring of the mRNA autophagy marker
levels in APPswePS1dE9
Wild-type APPswePS1dE9
Cortex Hippocampus Cortex Hippocampus
Beclin-1 1.00 ± 0.26 1.00 ± 0.18 1.22 ± 0.21 0.91 ± 0.05
p62 1.00 ± 0.12 1.00 ± 0.08 0.93 ± 0.12 1.10 ± 0.06
LC3 1.00 ± 0.07 1.00 ± 0.08 0.79 ± 0.05 0.82 ± 0.09
Total RNA was isolated from cortex and hippocampus of 12-month old
APPswePS1dE9 and WT mice and TaqMan real-time PCR was performed in an ABI
7500 real-time PCR system as described in Materials and methods. Results were
normalized relatively to mean of WT mice (n = 12).Beclin-1 levels were positively correlated with those of
TNF-α in cortex (rho = 0.60; P = 0.007). These correla-
tions mean that in the APPswePS1dE9 group, the
higher the IL-1β and TNF-α levels, the higher the
Beclin-1 expression.
Relationships between mTOR signaling pathway and
cytokine production were observed in 12-month old
APPswePS1dE9 mice. In hippocampus, TNF-α levels
were inversely correlated with the mTOR activation
(rho = − 0.46; P = 0.04). In cortex, IL-1β and TNF-α
levels were inversely correlated with the p70S6K acti-
vation (rho = − 0.48; P = 0.04 and rho = − 0.49; P = 0.03,
respectively). These correlations indicate that the higher
the IL-1β and TNF-α levels, the lower the mTOR signal-
ing pathway activation. Another interesting result is that
cortical levels of Beclin-1 expression were positively corre-
lated with those of p62 (rho = 0.75, P = 0.0002). This last
correlation would strengthen the results demonstrating a
Figure 5 Ultrastructure of cortex and hippocampus in 12-month old APPswePS1dE9 mice. Transmission electron microscopy (TEM) cortical
(A) and hippocampal (C) representative images (n = 3 mice) showed dystrophic neurites (marked by *) with a large accumulation of autophagic
vesicles (AVs). (B) represents a magnified region of interest (defined by a white square in image (a)) within many AVs with a dense compacted
amorphous or multilamellar content as indicated by white arrows.
Figure 6 Correlation between Beclin-1 and IL-1β levels in cortex and hippocampus of 12-month old APPswePS1dE9 mice. Spearman
correlations were performed between levels of IL-1β and Beclin-1 in the cortex (A) and hippocampus (B) of 12-month old APPswePS1dE9 mice
(n = 12). rho and P-values were indicated on graphs. The level of significance was P < 0.05.
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wePS1dE9 mice.
Discussion
There is mounting evidence that the control of autophagy
is impaired in AD as well as in many other neurodegenera-
tive diseases with protein aggregation [43,44]. Furthermore,
many studies have revealed that the stimulation of autoph-
agy can reduce Aβ accumulation and alleviate memory
deficits in transgenic AD mice [45-48]. As with many
other neurodegenerative diseases, AD is also marked
by a large inflammatory response and recent data are
consistent with the hypothesis that Aβ-induced activa-
tion of the NLRP3 inflammasome enhances AD pro-
gression by mediating a harmful chronic inflammatory
tissue response [11-13].
The crosstalk between autophagy and inflammation
is mainly described at peripheral level in particular in
inflammatory bowel diseases [49], type 2 diabetes [50],
cardiac disorders [51] and cystic fibrosis [52]. Recently,
we showed, in primary cultures of neurons, astrocytes
and microglia, that IL-1β induced autophagy with accu-
mulation of many acidic vesicles loaded with autophagic
markers (p62 and LC3) in microglia, whereas Aβ42 pre-
vented the effects of exogenous IL-1β in the production of
inflammatory factors and in autophagy impairment [53].
In this present study, we wanted to explore correlations
between autophagy and inflammation in vivo by using
APPswePS1dE9 mice which displayed amyloid plaques
and an inflammatory response at an early stage of the life
and progressively increase with age [37,38]. However, their
longitudinal status of autophagy has never been studied.
In three, six- and twelve-month old mice, results
showed that mice displayed a large increase in IL-1β and
TNF-α, a significant decrease in mTOR (a negative
regulator of autophagy) and Beclin-1 associated with
an accumulation of autophagic vacuoles (AVs) with a
dense compacted amorphous or multilamellar content
at twelve months of age in hippocampus and cortex.
Interestingly, correlation analyses showed that Beclin-1
was positively correlated with IL-1β and TNF-α and these
cytokine levels were inversely correlated with the levels of
mTOR activation at 12 months of age.
The monitoring of inflammation in APPswePS1dE9
versus WT mice at 3, 6 and 12 months of age showed
that APPswePS1dE9 mice displayed cytokine production,
in particular IL-1β in cortex at 12 months of age and
hippocampus from 6 months, but TNF-α levels increased
only in hippocampus at 12 months and were less than
10 pg/mg protein as previously described [37,38]. In line
with our work, Jin et al. did not find any modification of
the levels of IL-6. Similar changes in cytokine expression
have been shown in other transgenic mice and reflected
those observed in AD patients [54].Concerning autophagy, it is well-known that the mTOR
activation is a primordial inhibitory signal [55-59]. In these
APPswePS1dE9 mice, a large decrease of the activation
of mTOR and its downstream substrate p70S6K was
observed according to previous findings in other trans-
genic mouse AD models [60-63]. However, in some trans-
genic mouse models of AD, the mTOR activation was not
modified while the p70S6K activation decreased [64].
In two independent mouse models of AD, rapamycin,
through inhibition of mTOR signaling, rescued cogni-
tive deficits by suppressing extracellular Aβ deposition
and intracellular tau accumulation [45,63]. Interestingly,
this treatment induced autophagy marked by increased
expression of Atg 7, Atg5-Atg12, decrease in p62, no
modification of LC3 expression and controversial results
surrounding LC3-II expression in PDAPP and 3xTg-AD
mice [45,46]. In our experimental conditions, APPs-
wePS1dE9 mice not treated with rapamycin displayed a
large inactivation of mTOR signaling pathway from
6 months of age in hippocampus, a significant decrease
of Beclin-1 both in cortex and hippocampus and p62 in
cortex at 12 months of age, but no modification of
LC3-I and LC3-II expression. These decreases of autopha-
gic markers were significantly different from mice at three
and six months of age and were associated with extensive
accumulation of autophagic vesicles either with a dense
compacted amorphous or multilamellar content within dys-
trophic neurites as previously described in other AD trans-
genic mice [35,46,65,66] and in brains of AD patients [29].
Recent studies have demonstrated that the p62 gene
expression and cytoplasmic p62 protein levels are sig-
nificantly reduced in the frontal cortex of AD patients
compared to that of control subjects [32,67]. Here, no
modification of transcriptional expression was observed
while a large decrease of its protein expression was
quantified only in cortex of APPswePS1dE9 mice as in
cortex of AD patients. This decrease could be explained
by its sequestration into amyloid aggregates reducing
the accessibility of p62 protein for the regulation of
signaling, trafficking and autophagic clearance of ubiquiti-
nated proteins [68]. Moreover, studies in p62 knockout
mice have clearly demonstrated that the lack of p62 pro-
tein leads to the neuropathological lesions including the
accumulation of hyperphosphorylated tau and neurofibril-
lary tangles, synaptic deficiencies with loss of working
memory and neuronal apoptosis [69].
In addition, it was shown that an inhibition of p62
resulted in the formation of mis-regulated autophago-
somes with multilayer membranes and an autophagic
cell death in carcinoma cells [27]. The expression of
p62 is also determined by availability of lysosomal-
derived amino acids used for de novo synthesis of p62
[70]. However in AD, it is well-known that lysosomal
acidification is disrupted [71,72].
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caspase-cleavage as shown in frontal cortex tissue from
moderate to severe AD cases [66,73-75]. Some miRNA,
miR-30a and miR-376b target Beclin mRNA [76,77] and
miR-30a levels have been shown to increase in cerebro-
spinal fluid of AD patients [70]. Another explanation
for the reduced expression of Beclin-1 could be a non-
functional sequestration of Beclin-1 as it is a molecular
platform assembling an interactome, with stimulating
and suppressive components, which regulate the initiation
of the autophagosome formation [75]. In AD transgenic
mice, Beclin-1 reduced neuronal autophagy, disrupted
lysosomes, promoted intracellular and extracellular Aβ
accumulation, and resulted in neurodegeneration [35].
On the contrary, increased expression of it reversed
these impairments in mice [78,79]. Recent studies pos-
ition Beclin-1 as a link between autophagy, retromer
trafficking, and receptor-mediated phagocytosis [80].
Indeed, Beclin-1, together with its phosphatidylinositol
3-kinase (PI3K) binding partner, Vps34, played a role in
receptor-mediated phagocytosis by regulating the retro-
mer complex in microglia [80].
Interestingly, results showed positive correlation be-
tween Beclin-1 and IL-1β in cortex and hippocampus and
with TNF-α in cortex, suggesting relationships between
inflammatory response and autophagy impairment in
12-month old APPswePS1dE9 mice. It is known that
many inflammasomal receptors, in particular NLRP4,
could interact with Beclin-1 and inhibit autophagocy-
tosis [81]. Furthermore, the levels of these cytokines
were inversely correlated with the activation of mTOR
signaling pathway. It is known that the mTOR signal-
ing pathway can inhibit the inflammatory response in
microglia and monocytes by reducing NF-κB activation
and enhancing STAT3 activity and anti-inflammatory
IL-10 production [82,83], whereas inhibition of mTOR
with or without rapamycin has reciprocal effects [84-86].
Therefore, in the APPswePS1dE9 mouse model, the inhib-
ition of the mTOR signaling pathway could participate in
the inflammatory response which could impair autophagy.
However, mTORC1 colocalizes with the Transcription
Factor EB (TFEB), a master regulator of lysosomal biogen-
esis on the lysosomal membrane, leading to inhibition of
TFEB activity by mTORC1-induced phosphorylation.
Conversely, pharmacological inhibition of mTORC1, as
well as starvation and lysosomal disruption, activates
TFEB by promoting its nuclear translocation for lyso-
somal biogenesis and autophagy [87-90]. However, in
the APPswePS1dE9 mouse model there was an accumu-
lation of AVs that may have been due to a dysfunction
of lysosomal activity. It is known that mutation of PS1
leads to the accumulation of immature unglycosylated
v-ATPase which is needed in the acidification of autoly-
sosomes and/or lysosomes with abnormal accumulationof late-stage autophagosomes with undigested contents
just like the ultrastructures present in AD neurons
[71,72,91]. Recently, inhibition of GSK-3β or cystatin B,
an endogenous cathepsin inhibitor, could restore lyso-
somal acidification that in turn enables clearance of Aβ
burdens and reactivation of mTOR. These changes fa-
cilitate amelioration in cognitive function in 5×FAD and
TgCRND8 mice [48,60].
For LC3, no variation is observed in APPswePS1dE9
mice regardless of age compared to WT mice. Other
authors show no modification of LC3-I [45,46]. For
LC3-II isoform, the results in the literature are contradict-
ory despite the absence of variation of LC3-I. Indeed,
some have observed an increase in the expression of
LC3-II at a very late age of 18 months in 3xTg-AD
treated with rapamycin, which is known to inhibit mTOR
and thus induce autophagy [46]. Other APP/PS1 mice
(PS1M146L/APP751SL) aged 18 months also showed an
accumulation of LC3-II in microsomal fractions and very
little in the synaptosomes [92]. Other authors showed a
decrease of LC3-II in PDAPP mice at the age of eight to
nine months although treated for thirteen weeks with
rapamycin since the age of four months [45].
Therefore, the expression rate of LC3-II varies depend-
ing on the age of the mice and its subcellular localization.
Furthermore, we cannot exclude a variation depending on
the transgenic AD model.
Conclusion
Taken together, these results highlighted the negative
impact of IL-1β and TNF-α in the activation of the mTOR
signaling pathway (negative correlation) and in the induc-
tion of autophagy (positive correlation with Beclin-1) which
remained locked and led to the accumulation of AVs in
APPswePS1dE9 at 12 months of age. This first demon-
stration of the relationships between inflammation and
autophagy in vivo should into account in new therapeutic
strategies to prevent inflammation and/or stimulate au-
tophagy in advanced neurodegenerative process such as
AD. Furthermore, development of similar but inactive
molecules to Beclin-1 could limit its non-functional se-
questration and allow the maintenance of a sufficient level
of free active Beclin-1 to initiate autophagic flux.
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